Company Directory / research

PrivateFor profitresearchNorwich, United Kingdom
Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.
Size
1-10 people: larger than 0% of companies with a size listed
Age
8 years old.
Reach
No web traffic ranking listed.
BiotechnologyHealth CareLife Science
Funding, as listed
$10M currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Ikarovec, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Ikarovec may be growing as it has entered a preclinical phase, indicating progress in its development pipeline. The company's gene therapy advancements are being supported by Rentschler's Stevenage site, which is dedicated to the bioprocess advancement of AAV material for pre-clinical testing of Ikarovec's gene therapies. This collaboration suggests an expansion of Ikarovec's operational capabilities and a commitment to advancing its gene therapy research.
Summaries written by the source dataset, not by us, and not checked.
research in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.